SIRPA and neoplasm: Tumor cells express high level of CD47 to escape immune surveillance initiated by macrophages (Chao et al., 2010; Majeti et al., 2009; Willingham et al., 2012), which leads to the development of CD47-SIRPα blockade as a promising approach for cancer therapy (Feng et al., 2019).